**Paul Ho Yeong Song, Ph. D.**

[paulhys@gmail.com](mailto:paulhys@gmail.com)

82-10-9284-3273

* 2015-current: Vice President, Samsung Bioepis, Leader of Next Generation Product Team/Cell Engineering Team
  + Supervised ~50 scientists focused on production cell line generation for the next generation biosimilar pipelines, and technology development for high titer cell line/vector system
  + Portfolio expansion strategies that will complement current biosimilar pipelines that include oncology and immunology targets
* 2010-2014: Vice President, Samsung Advanced Institute of Technology, Head/Bio Therapeutics Lab
  + Responsible for hiring key talents with focuses on oncology target discovery, antibody & protein engineering, and expanded from 3 member group to 60 member lab in 2 yrs
  + Internalized key technology platforms that are crucial for innovative antibody discovery & engineering and that would allow Samsung to quickly catch up with global biopharma companies
  + Generated two best-in-class antibodies targeting oncology indications w/ unique mechanism of actions, one of which is in phase I clinical study now after successful preclinical development
* 2003- 2009: Principle Research Scientist, Lilly Research Laboratories, BioRTP
  + Championed antibody-based oncology biomarker discovery/development against several preclinical/clinical assets for patient stratification and clinical PD assessment
  + Led cross-functional new target identification group utilizing the cDNA libraries encoding novel secreted proteins and high throughput phenotypic drug screen using a variety of cell based assays
  + Led antibody engineering group utilizing phage display & codon-based mutagenesis
* 1997-2002: Senior Biologist, Lilly Research Laboratories, BioRTP
  + Led an interdisciplinary effort of 5 PhDs, 7 associates, and 3 outside collaborators for several anti-inflammatory targets
  + Led development of several in vivo efficacy models targeting inflammation (acute lung injury, acute liver failure, sepsis, UC & GVHD models)
* 1995-1997: Post Doc Fellow, Tularik Inc (Amgen SF)
  + Cloned and characterization of IKKa, a kinase critically involved in TNF signal transduction & an important target against inflammation and cancer
* 1992-1994: Post Doc Fellow, Indiana Univ Med School
  + Identified several TNFR binding proteins, leading to better understanding of TNF signal transduction mechanism

Education

* Ph. D. Biology (1990) Purdue University, W. Lafayette, IN, USA
* M.S. Biology (1988) Purdue University, W. Lafayette, IN, USA
* B. A. Biology (1986) University of Virginia, Charlottesville, VA, USA

Publication

Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y, He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I, Koh GY. Amelioration of sepsis by TIE2 activation-induced vascular protection.

Sci Transl Med. 2016 Apr 20;8(335):335ra55.

Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, Song PH, Kim KA, Weiner LM. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene. 2015 Feb 26;34(9):1083-93

Oh YM, Lee SB, Choi J, Suh HY, Shim S, Song YJ, Kim B, Lee JM, Oh SJ, Jeong Y, Cheong KH, Song PH, Kim KA. USP8 modulates ubiquitination of LRIG1 for Met degradation. Sci Rep. 2014 May 15;4:4980

Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, Jung S, Choi J, Lee S, Cheong KH, Kim DU, Park HW, Han YK, Kim GW, Choi H, Song PH, Kim KA. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene. 2014 Jan 2;33(1):34-43

Oh YM, Song YJ, Lee SB, Jeong Y, Kim B, Kim GW, Kim KE, Lee JM, Cho MY, Choi J, Nam DH, Song PH, Cheong KH, Kim KA. A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells. 2012 Dec;34(6):523-9.

Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, Kim H, Seol HJ, Kong DS, Lee JI, Rich JN, Lee J, Nam DH. MET signaling regulates glioblastoma stem cells.

Cancer Res. 2012 Aug 1;72(15):3828-38.

Matute-Bello G,Frevert CW, Liles WC, Ballman K, Wong V, Green RR, Nakamura M, Song, HY, Witcher D, Jakubowski JA and Martin TR. Blockade of the Fas/FasL system with FLINT, a novel decoy receptor 3 analogue, in mice with experimental pneumococcal pneumonia. J Infect. Diseases, 2005, 191:596-606

SchmidtCS, LiuJ, Zhang T, Song HY, Sandusky G, Mintze K, Benschop RJ, Glasebrook A, Yang DD, and Na S. Enhanced B cell Expansion, Survival and Humoral Responses by Targeting Death Receptor 6. J of Experimental Medicine, 2003, 197:51-62

Liu J, Schmidt CS, Zhao F, Okragly AJ, Glasebrook A, Fox N, Galbreath E, Zhang Q, Song HY, Na S, Yang DD. LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function. Int Immunol. 2003, 15:861-70.

Wroblewski VJ, Witcher DR, Becker GW, Davis KA, Dou S, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE. Decoy Receptor 3 (DcR3) is proteolytically processed to ma metabolic fragment having differential activities against Fas Ligand and LIGHT. Biochemical Pharmacol, 2003, 65:657-667

Wortinger MA, Foley JW, Larocque P, Witcher DR, Lahn M, Jakubowski JA, Glasebrook A, Song HY. Fas ligand-induced murine pulmonary inflammation is reduced by a stable DcR3 analogue. Immunology 2002, 110:225-233

Liu J, Heuer JG, Na S, Galbreath E, Zhang T, Yang DD, Glasebrook A, Song HY.

Accelerated onset and increased severity of acute graft-versus-host disease following adoptive transfer of DR6-deficient T cells. J Immunol. 2002,169:3993-8.

Liu J, Na S, Glasebrook A, Fox N, Solenberg PJ, Zhang Q, Song HY, Yang DD. Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice.  
Immunity. 2001, 15:23-34.

Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A. 1997, 94:9792-6.

Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappaB kinase. Cell. 1997, 90:373-83.

Dunbar JD, Song HY, Guo D, Wu LW, Donner DB. Two-hybrid cloning of a gene encoding TNF receptor-associated protein 2, a protein that interacts with the intracellular domain of the type 1 TNF receptor: identity with subunit 2 of the 26S protease. J Immunol. 1997 May 1;158(9):4252-9.

Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6721-5.

Broxmeyer HE, Cooper S, Li ZH, Lu L, Song HY, Kwon BS, Warren RE, Donner DB.

Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol. 1995 Dec;62(4):203-15.

Song HY, Donner DB. Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumour necrosis factor receptor. Biochem J. 1995 Aug 1;309 ( Pt 3):825-9.

Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem. 1995 Mar 24;270(12):6729-33.

Song HY, Dunbar JD, Zhang YX, Guo D, Donner DB. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J Biol Chem. 1995 Feb 24;270(8):3574-81.

Tauchi T, Feng GS, Shen R, Song HY, Donner DB, Pawson T, Broxmeyer HE. SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J Biol Chem. 1994 269:15381-15387.

Elkins PA, Song HY, Cramer WA, Stauffacher CV. Crystallization and characterization of colicin E1 channel-forming polypeptides. Proteins. 1994 Jun;19(2):150-7.

Song HY, Dunbar JD, Donner DB. Aggregation of the intracellular domain of the type 1 tumor necrosis factor receptor defined by the two-hybrid system. J Biol Chem. 1994 Sep 9;269(36):22492-5.

Cramer WA, Zhang YL, Schendel S, Merrill AR, Song HY, Stauffacher CV, Cohen FS.

Dynamic properties of the colicin E1 ion channel. FEMS Microbiol Immunol. 1992 Sep;5(1-3):71-81.

Cramer WA, Cohen FS, Stauffacher CV, Zhang YL, Merrill AR, Song HY, Elkins P. Structure-function for the colicin E1 channel: Voltage-driven translocation and gating of a tetra (or hexa) helix channel. Bacterial plasmid-coded toxins:Bacteriocins, Microcins and Lantibiotics (R James, C. Lazdunski, F. Pattus eds) pp. 139-150. Springer-Verlag, Heidelberg

Song HY, Cramer WA. Membrane topography of ColE1 gene products: the immunity protein. J Bacteriol. 1991 May;173(9):2935-43.

Song HY, Cohen FS, Cramer WA. Membrane topography of ColE1 gene products: the hydrophobic anchor of the colicin E1 channel is a helical hairpin. J Bacteriol. 1991 May;173(9):2927-34.

Cramer WA, Cohen FS, Merrill AR, Song HY. Structure and dynamics of the colicin E1 channel. Mol. Microbiol. 1990 4:519-526

Aronson AI, Song HY, Bourne N. Gene structure and precursor processing of a novel Bacillus subtilis spore coat protein. Mol. Microbiol. 1989 3:437-444